Physician profile
Brian S Anding
NPI 1730103649
$1,155.78
in general payments reported to CMS, 2019-2025
18 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $58.75 · 2021: $112 · 2022: $81.77 · 2023: $194 · 2024: $411 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $373.60 | 2023-2025 | Argos, Clareon, Centurion |
| Abbvie INC. | $195.15 | 2022-2024 | Lumigan, Alphagan P, Durysta |
| Janssen Pharmaceuticals, INC | $117.19 | 2019 | |
| Aerie Pharmaceuticals, INC. | $72.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $67.44 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $43.37 | 2024 | Envista Mx60 Iol |
| Allergan, INC. | $38.34 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $32.77 | 2024 | Xdemvy |
| Glaukos Corporation | $30.64 | 2024 | Idose |
| Oyster Point Pharma, INC. | $26.13 | 2023 | Tyrvaya |
| Glaxosmithkline, LLC. | $24.39 | 2025 | Blenrep |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.97 | 2019 | |
| Horizon Therapeutics Plc | $22.33 | 2021 | |
| Dompe US, INC. | $19.72 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $18.85 | 2020 | |
| Amgen INC. | $15.24 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Anding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.